ADC Therapeutics SA (ADCT) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN USH0036K1476
ADC Therapeutics SA financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 81.36 m USD |
| Gross profit | 75.56 m USD |
| Operating income | -121.50 m USD |
| EBIT | -98.79 m USD |
| Net income | -142.62 m USD |
| Diluted EPS – continuing operations | -1.12 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
More stocks
- Daldrup & Soehne (4DS.DE)
- Ordinary Fully Paid Deferred Settlement (HGODB.AX)
- Sensortek Technology Corp (6732.TWO)
- Asia Network International PCL (ANI.BK)
- Asia Sermkij Leasing Public Company Limited (ASK.BK)
- Silicom (SILC)
- Chunil Express (000650.KS)
- Delta Asia International Corporation (6762.TWO)
- Vef AB (VEFAB.ST)
- SNS (0259.KL)
- Hong Pu Real Estate Development Co Ltd (2536.TW)
- Kyeryong Const (013580.KS)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.